scholarly journals Simultaneous LC-MS/MS-Based Quantification of Free 3-Nitro-l-tyrosine, 3-Chloro-l-tyrosine, and 3-Bromo-l-tyrosine in Plasma of Colorectal Cancer Patients during Early Postoperative Period

Molecules ◽  
2020 ◽  
Vol 25 (21) ◽  
pp. 5158
Author(s):  
Mariusz G. Fleszar ◽  
Paulina Fortuna ◽  
Marek Zawadzki ◽  
Bogna Kosyk ◽  
Małgorzata Krzystek-Korpacka
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Postoperative Period ◽  
Solid Phase ◽  
Surgical Site Infections ◽  
Perioperative Period ◽  
Early Postoperative Period ◽  
Specificity And Sensitivity ◽  
Liquid Chromatography Tandem Mass ◽  
Colorectal Cancer Patients

Quantification with satisfactory specificity and sensitivity of free 3-Nitro-l-tyrosine (3-NT), 3-Chloro-l-tyrosine (3-CT), and 3-Bromo-l-tyrosine (3-BT) in biological samples as potential inflammation, oxidative stress, and cancer biomarkers is analytically challenging. We aimed at developing a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based method for their simultaneous analysis without an extract purification step by solid-phase extraction. Validation of the developed method yielded the following limits of detection (LOD) and quantification (LOQ) for 3-NT, 3-BT, and 3-CT: 0.030, 0.026, 0.030 ng/mL (LODs) and 0.100, 0.096, 0.098 ng/mL (LOQs). Coefficients of variation for all metabolites and tested concentrations were <10% and accuracy was within 95–105%. Method applicability was tested on colorectal cancer patients during the perioperative period. All metabolites were significantly higher in cancer patients than healthy controls. The 3-NT was significantly lower in advanced cancer and 3-BT showed a similar tendency. Dynamics of 3-BT in the early postoperative period were affected by type of surgery and presence of surgical site infections. In conclusion, a sensitive and specific LC-MS/MS method for simultaneous quantification of free 3-NT, 3-BT, and 3-CT in human plasma has been developed.

Nutritional status of colorectal cancer patients and its changes during primary treatment

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13577-13577
Author(s):  
L. Meyer ◽  
I. Gastinger
Keyword(s):  
Colorectal Cancer ◽  
Nutritional Status ◽  
Cancer Patients ◽  
Postoperative Period ◽  
Cell Mass ◽  
Prognostic Significance ◽  
Impedance Analysis ◽  
Primary Treatment ◽  
Early Postoperative Period ◽  
Colorectal Cancer Patients

13577 Background: The nutritional status of oncological patients has become a subject of growing scientific interest because of its prognostic significance and the resulting therapeutic possibilities. Apart from the documentation of the nutritional status at the time of diagnosis the influence of the intensive primary treatment plays a major role. Methods: From October 2002 to December 2004 data on the nutritional status of 106 colorectal cancer patients were documented prospectively. The primary assessment of the nutritional status was performed with the SGA (Subjective Global Assessment). Additionally, a Body Impedance Analysis (BIA) was carried out and repeated at the day of surgery and the fivth and tenth postoperative day. Results: In the three groups according to the SGA (A: well nourished, B: moderately malnourished, C: severely malnourished) we found 27 patients to be group A, 76 patients group B and only 3 patients group C. The data of the BIA showed phase angle of 5.7°, 5.0° and 3.7°, the index of Extracellular Mass and Body Cell Mass (ECM/BCM) the figures 0.8, 1.0 and 1.6. The data remained in the same range up to the day of surgery and got worse in the early postoperative period (until 5. postoperative day). In the late postoperative (day 6 to 10) we could notice a stabilisation, the preoperative values were not achieved until demission. Conclusions: Patients with colorectal cancer are moderately malnourished in about 75%, but severely malnourished in only very few cases. The period of preoperative diagnostics does not lead to an impairment of the nutritional status. After surgery and in the early postoperative period the nutritional status is considerably affected and does not reach the primary level until demission. In this field the multimodal perioperative concepts seem to be a chance to diminish the nutritive deficit and to discharge the patient in a better condition after primary treatment. No significant financial relationships to disclose.

scholarly journals Copper-Zinc ratio and nutritional status in colorectal cancer patients during the perioperative period

2016 ◽  
Vol 31 (suppl 1) ◽  
pp. 24-28 ◽  
Author(s):  
Sofia Miranda de Figueiredo Ribeiro ◽  
Amanda Maria Tomazini Munhoz Moya ◽  
Camila Bitu Moreno Braga ◽  
Fernanda Aparecida Domenici ◽  
Marley Ribeiro Feitosa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Nutritional Status ◽  
Cancer Patients ◽  
Perioperative Period ◽  
Copper Zinc ◽  
Colorectal Cancer Patients

Ultra-high-quality sequencing assay for comprehensive genetic panel analysis of tumor-derived circulating cell-free DNA in colorectal cancer patients.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 504-504
Author(s):  
Jeeyun Lee ◽  
Stefanie Mortimer ◽  
Gangwu Mei ◽  
Dragan Sebisanovic ◽  
LaiMun Siew ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Residual Disease ◽  
Acquired Resistance ◽  
Cancer Cell Line ◽  
The Body ◽  
High Quality ◽  
Primary Tumors ◽  
Specificity And Sensitivity ◽  
Colorectal Cancer Patients

504 Background: Current approaches based on invasive biopsy genetic analysis can fail to capture an accurate picture of the real-time cancer profile due to limited spatial window of biopsy into residual disease throughout the body. Moreover, tumor rebiopsy has significant challenges to be widely used in practice for serial monitoring of disease progression or acquired resistance. Analysis of circulating tumor nucleic acids (ctDNA), on the other hand, presents a new tool for the monitoring and treatment of cancer. However, due to high-quality false positives in current NGS assays, the majority of studies on ctDNA have been limited to hotspot analyses, and typically only involve patients where ctDNA fractions are high (>1-5%). Methods: We have developed a differentiated sequencing assay, Digital Sequencing Technology (DST) that enables detection of rare genomic abnormalities with ultra high-specificity and sensitivity. Our assay is able to eliminate the error and distortion created by sample-prep and sequencing processes in standard NGS workflows and produce near-perfect representations of all rare variants. Results: We have shown that in sequencing a comprehensive cancer panel of 80kbp in 0.1% cancer cell line titration samples, standard Illumina SBS generates many high-quality false positive variant calls in the range of 0.05-5%, while our assay resulted in highly sensitive and completely error-free variant calls across the entire panel. We then profiled ctDNA and matched primary tumor samples in more than 50 plasma samples collected from metastatic colorectal cancer patients. We found mutations in ctDNA with allele frequencies in the range of 0.05-40%. We established the concordance of ctDNA mutations with different clones within primary tumors. We further investigated the potential clinical usefulness of discordant mutants based on the treatment history of each patient. Conclusions: This work indicates the remarkable potential of using our assay in deep analysis of ctDNA, thereby allowing researchers and clinicians to comprehensively and non-invasively monitor the genetic dimension of cancer throughout the body.

Prognostic value of circulating cytokines in colorectal cancer: A prospective study in sixty colorectal cancer patients in Tunisia.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e15130-e15130
Author(s):  
Jihene Braham Ayari ◽  
Rania Guesmi ◽  
Mehdi Balti ◽  
Mouna Ben Azaiz ◽  
Aref Zribi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Solid Phase ◽  
Young Patients ◽  
Serum Samples ◽  
Metastatic Setting ◽  
The Mean ◽  
High Level ◽  
Colorectal Cancer Patients ◽  
Circulating Cytokines

e15130 Background: Colorectal cancer is the third most common malignancy and fourth most common cause of cancer mortality worldwide. It is responsible for more than 600,000 deaths annually, and incidence rates are increasing in most of the developing countries. Pathophysiology implicates pro-inflammatory conditions that promote the tumor malignant progression, invasion, and metastasis. The aim of this study is to measure the level of circulating cytokines (IL1b, IL6, IL8, IL10, IL22, IL23 and TNFα) in sixty colorectal cancer patients in Tunisia and to evaluate their implication as prognostic factors. Methods: Serum samples were collected prospectively from a cohort of sixty colorectal cancer patients in Tunisia. Levels of circulating inflammatory cytokines, TNF-α, IL1b, IL6 and IL8 were measured using the technique of a solid-phase, two-site chemo-luminescent enzyme immune-metric assay (Immulite 1000, Simens, USA). Serum levels of IL10 were measured by enzyme-linked immunosorbent assays (ELISA) sandwich method. Results: The mean age of patients is 58 years (24–82 years), Thirty-sex among them were m and 24 women with sex ratio of 1.5. Twenty-five patients were at metastatic setting, and hepatic metastasis was found in 25% of cases. The mean level of cytokines Il6, IL10, TNFα, IL8 and IL1b were respectively 12.26 +/- 18.7 pg/ ml (min 2, max 117pg/ ml), 0.93 +/- 5.23 pg/ ml (min 0, max 39.35 pg/ml), 8.31 +/- 4.99 pg/ ml (min 4, max 27.20 pg/ ml), 61.9 +/- 159.71 pg/ml (min 5, max 1173 pg/ ml) and 1.13 +/- 3.34 pg/ ml (min 5, max 15.7pg/ml. We found a significant correlation between a high level of IL8 and metastatic disease (p=0.001), especially in mutant RAS cases (p=0.001). We found also a significant correlation between high level of IL1b and lymphovascular invasion (p=0.013) and young patients (p=0.01). On the other hand, there was significant correlation between IL8 and IL6 (r = 0.560, p = 0.00001); IL8 and TNFα (r = 0.404, p = 0.001); and IL10 with IL1b (r = 0.297, p = 0.021). Conclusions: Our results highlight the role of circulating IL8, TNFα, IL1b and IL10 as potential prognostic biomarkers in colorectal cancer patients. These cytokines could contribute to tumor growth and progression, namely for IL-8 level that was significantly correlated with poor prognosis and advanced stages. This correlation needs to be evaluated in large prospective trials and suggests a rational for the development and use of cytokine blockade in treatment of colorectal cancer patients.

scholarly journals The Effect of Anesthesia on the Immune System in Colorectal Cancer Patients

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Yangjie Dang ◽  
Xingxing Shi ◽  
William Xu ◽  
Mingzhang Zuo
Keyword(s):  
Colorectal Cancer ◽  
Immune System ◽  
Stress Response ◽  
Cancer Patients ◽  
Surgical Excision ◽  
Perioperative Period ◽  
Postoperative Recurrence ◽  
High Morbidity ◽  
Cancer Dissemination ◽  
Colorectal Cancer Patients

Colorectal cancer (CRC) is the key leading cause of high morbidity and mortality worldwide. Surgical excision is the most effective treatment for CRC. However, stress caused by surgery response can destroy the body’s immunity and increase the likelihood of cancer dissemination and metastasis. Anesthesia is an effective way to control the stress response, and recent basic and clinical research has shown that anesthesia and related drugs can directly or indirectly affect the immune system of colorectal cancer patients during the perioperative period. Thus, these drugs may affect the prognosis of CRC surgery patients. This review is intended to summarize currently available data regarding the effects of anesthetics and related drugs on perioperative immune function and postoperative recurrence and metastasis in CRC patients. Determining the most suitable anesthesia for patients with CRC is of utmost importance.

scholarly journals Are colorectal cancer patients at risk for COVID-19 infection during the postoperative period? The Covid-GRECCAR study

2021 ◽  
Vol 36 (3) ◽  
pp. 611-615
Author(s):  
Jean-Jacques Tuech ◽  
◽  
Gilles Manceau ◽  
Mehdi Ouaissi ◽  
Christine Denet ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
At Risk ◽  
Cancer Patients ◽  
Postoperative Period ◽  
Patients At Risk ◽  
Colorectal Cancer Patients

scholarly journals FDG-PETCT versus contrast-enhanced computed tomography in diagnosis of post-therapeutic colorectal cancer recurrence and metastases

2020 ◽  
Vol 51 (1) ◽  
Author(s):  
Nivine Abdel Moneim Chalabi ◽  
Reem Hassan Bassiouny ◽  
Mohamed Abobakr El Sedek
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Hepatic Metastases ◽  
Focal Lesions ◽  
Curative Surgery ◽  
Contrast Enhanced Ct ◽  
Specificity And Sensitivity ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Colorectal Cancer Patients

Abstract Background This study was designed to assess the role of 18F-FDG CT was able to detect additional/CT in post-therapeutic surveillance of colorectal cancer patients as compared with contrast-enhanced CT to allow early detection of recurrent and metastatic cases amenable for curative surgery and thus improve the overall survival of patients. Results Of the total 100 patients, 70 proved to have metastasis or local recurrent disease by the standard reference modalities. One hundred eighty-two diseased regions were detected in these 70 patients. PET/CT was positive in 174 regions (95.6%) whereas CECT was positive in 118 regions (64.8%). PET/CT was superior to CECT in detection of hepatic focal lesions, metastatic lymph nodes, pulmonary metastases, and peritoneal and suprarenal metastases whereas both were equal in detection of osseous deposits. CECT detected four lesions that were missed by PET/CT, and these were hepatic metastases from mucinous adenocarcinoma. Conclusion PET/CT is a better method to evaluate post-therapeutic colorectal cancer patients. It detected viable residual tumor cells in operative bed scar, small LNs, hepatic focal lesions, peritoneal deposits, pulmonary masses, bone deposits, and suprarenal deposits with significantly higher specificity and sensitivity than CECT avoiding unnecessary surgeries.

scholarly journals Determination of VOCs in Surgical Resected Tissues from Colorectal Cancer Patients by Solid Phase Microextraction Coupled to Gas Chromatography–Mass Spectrometry

2021 ◽  
Vol 11 (15) ◽  
pp. 6910
Author(s):  
Nicoletta De Vietro ◽  
Antonella Maria Aresta ◽  
Arcangelo Picciariello ◽  
Maria Teresa Rotelli ◽  
Carlo Zambonin
Keyword(s):  
Colorectal Cancer ◽  
Mass Spectrometry ◽  
Gas Chromatography ◽  
Cancer Patients ◽  
Solid Phase Microextraction ◽  
Solid Phase ◽  
Gas Chromatography Mass Spectrometry ◽  
Volatile Organic ◽  
Colorectal Cancer Patients

Early diagnosis of colorectal cancer is crucial to increase the survival rates of the patients and breath analysis represents a promising non-invasive tool to obtain information on cancer-related variations on the human volatilome. A solid phase microextraction coupled to gas chromatography–mass spectrometry method for the determination of seven selected compounds, representative of the volatilome secreted by the colonic mucosa of patients affected by colorectal cancer, including benzaldehyde, benzoic acid, dodecane, ethylbenzene, octanal, tetradecane and toluene, was developed. All the extraction parameters were studied for both headspace and direct immersion sampling and the procedures fully validated. The potential of the approach was demonstrated by the time monitoring of the emission of the selected volatile organic compounds from the surgical resected colon mucosa tissues of colorectal cancer patients. Furthermore, the extraction and identification of thirty-one volatile organic compounds secreted by the same tissues was accomplished.

Sign in / Sign up

Export Citation Format

Share Document